<p>Basic leucine zipper (bZIP) transcription factors can have an oncogenic role in cancer development. Nuclear factor erythroid related 2-factor 2 (Nrf2) is a bZIP transcription factor that traditionally is thought of as a cellular protector. In normal cells, Nrf2 is only activated after exposure to reactive oxygen species or electrophiles and induces expression of antioxidant and detoxification genes. However, in many cancers (<i>e.g.,</i> lung, pancreatic, and breast) Nrf2 is constitutively activated and is associated with poor overall survival and intrinsic resistance to anticancer therapies. Nrf2 heterodimerizes with transcription factors small musculoaponeurotic fibrosarcoma Maf (sMAF) proteins (e.g., MafG) in the nucleus and binds DNA, inducing transcription of Nrf2 target genes, conferring chemotherapeutic resistance to cancer cells. c-Myc another bZIP transcription factor is often overexpressed in a variety of cancers and acts like a protooncogenic transcriptional regulator. Mutations that drive abnormal MYC expression are the most common cariogenic event in tumor progression. c-Myc heterodimerizes with Max, its obligate bHLH-LZ heterodimerization partner, to form an active transcriptional state and induces DNA transcription. Hence inhibiting the interaction between c-Myc-Max and Nrf2-MafG will not only prevent bZIP heterodimerization but also DNA binding and downstream functions of c-Myc and Nrf2 that promote carcinogenesis. Stapled peptides, with their ability to target large surface area interactions, have shown promise for specifically inhibiting protein-protein interactions. Stapled peptides have improved cell permeability and oral bioavailability when compared to biologics. We have designed and synthesized stapled peptide for Nrf2/MafG interaction inhibition and stapled peptides for c-Myc/Max heterodimerization inhibition. Nrf2/MafG inhibition using the synthesized stapled peptide N1S, was demonstrated by luciferase and fluorescence polarization assays. Overall, we hypothesize that stapled peptides will be an effective therapeutic strategy resulting in decreased chemotherapeutic resistance and cancer cell proliferation.</p>
| Identifer | oai:union.ndltd.org:purdue.edu/oai:figshare.com:article/23802285 |
| Date | 31 July 2023 |
| Creators | Ramya Modi (16705938) |
| Source Sets | Purdue University |
| Detected Language | English |
| Type | Text, Thesis |
| Rights | CC BY 4.0 |
| Relation | https://figshare.com/articles/thesis/_b_STAPLED_PEPTIDES_AS_DIRECT_INHIBITORS_OF_ONCOGENIC_TRANSCRIPTION_FACTORS_b_/23802285 |
Page generated in 0.0034 seconds